Clinical Focus ›› 2025, Vol. 40 ›› Issue (3): 243-250.doi: 10.3969/j.issn.1004-583X.2025.03.009

Previous Articles     Next Articles

Clinical efficacy and safety of drug-eluting beads for bronchial artery chemoembolization versus conventional bronchial artery chemoembolization alone for advanced non-small cell lung cancer

Huang Xingzhou1, Zheng Weihua2, Zhang Shutong2, Chen Yanhao2()   

  1. 1. Department of Radiology, Hong’an County People’s Hospital, Huanggang 438400,China
    2. Department of Radiology, Wuhan Central Hospital, Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430014,China
  • Received:2024-10-17 Online:2025-03-20 Published:2025-03-25
  • Contact: Chen Yanhao E-mail:haohao101701@126.com

RichHTML

2

PDF (PC)

11

Abstract:

Objective To compare the clinical efficacy and safety of drug-eluting beads bronchial artery chemoembolization (DEB-BACE) versus conventional BACE alone in the treatment of advanced non-small cell lung cancer (NSCLC). Methods A retrospective analysis was conducted in 52 patients with primary NSCLC who were treated with DEB-BACE or conventional BACE alone in Wuhan Central Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology from January 2020 to March 2024. All patients had local progression or intolerability after the first-line treatment, such as systemic chemotherapy, radiotherapy, targeting, and immunization. According to the different interventional treatment regimens, they were divided into the DEB-BACE group (n=25) and conventional BACE group (cBACE group, n=27). The short-term clinical efficacy, progression-free survival (PFS), overall survival (OS), and postoperative adverse events were compared between the two groups. Results There was no significant differences in preoperative baseline data between the two groups (P>0.05). Complete remission was 0 at 1 month, 3 months, 6 months and 12 months postoperatively. There were significant differences in the 6-month objective response rate ( 44.0% vs 14.8%, χ2=5.387, P=0.020) and 6-month disease control rate (84.0% vs 55.6%, χ2=4.930, P=0.026) between the two groups (P<0.05). The incidence of postoperative adverse events in the DEB-BACE group was significantly lower than that of the cBACE group (P<0.05). There were no serious adverse complications, such as spinal cord loss and ectopic embolism in both groups. As of September 2024, all patients were followed up for 6-34 months, with an average follow-up time of (13.2±6.6) months. Compared with the cBACE group, the median PFS and median OS of the DEB-BACE group were significantly better (P<0.05). Conclusion The use of CalliSpheres drug-eluting beads loaded with gemcitabine for BACE demonstrated a superior clinical efficacy compared to cBACE alone in the treatment of advanced NSCLC. It has a lower rate of postoperative adverse events, suggesting a new, safe, and effective treatment option for advanced NSCLC.

Key words: carcinoma, non-small-cell lung, drug-eluting beads, chemoembolization, treatment outcome, safety

CLC Number: